Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease

• Published in: The American journal of cardiology 1995-12, Vol.76 (17), p.1259-1265
• Main Authors: Barr, Craig S., Lang, Chim C., Hanson, Jacqueline, Arnott, Michael, Kennedy, Norman, Struthers, Allan D.
• Format: Article
• Language: English
• Subjects: Aged; Animals; Cardiac arrhythmia; Coronary Disease - complications; Coronary Disease - physiopathology; Double-Blind Method; Drug therapy; Drug Therapy, Combination; Female; Heart - drug effects; Heart attacks; Heart Failure - complications; Heart Failure - drug therapy; Heart Failure - metabolism; Heart Failure - physiopathology; Hemodynamics - drug effects; Humans; Kidney Function Tests; Magnesium - metabolism; Male; Medical research; Mineralocorticoid Receptor Antagonists - pharmacology; Mineralocorticoid Receptor Antagonists - therapeutic use; Myocardium - metabolism; Prospective Studies; Rats; Rats, Sprague-Dawley; Spironolactone - pharmacology; Spironolactone - therapeutic use
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/S0002-9149(99)80353-1

In chronic heart failure, a diuretic plus an angiotensin-converting enzyme (ACE) inhibitor only partially suppresses aldosterone despite the fact that aldosterone has many harmful effects independent of angiotensin II. These possible harmful effects of aldosterone are magnesium loss, increased cardiac sympathetic activity, and increased ventricular arrhythmias. We have therefore assessed whether adding the aldosterone antagonist, spironolactone, to a loop diuretic and ACE inhibitor reverses any of these potentially harmful effects of residual aldosterone. In a preliminary animal study, we found that exogenous aldosterone reduced myocardial norepinephrine uptake by 24% in anesthetized rats in vivo. In our main study, 42 patients with New York Heart Association II to III congestive heart failure were randomized to spironolactone (50 to 100 mg/ day, titrated to blood pressure and plasma potassium) or placebo in a double-blind fashion. Our principal finding is that cardiac norepinephrine uptake as assessed by 123I-metaiodobenzylguanidine scintigraphy increased with spironolactone (p < 0.01). Spironolactone also elevated plasma magnesium (p < 0.05), reduced urinary magnesium excretion (p < 0.05), and caused a reduction in ventricular arrhythmias on 24-hour ambulatory electrocardiography (p < 0.05). Spironolactone increased plasma renin activity, plasma aldosterone (p < 0.01), 24-hour urinary sodium excretion (p < 0.05), and urinary sodium/potassium ratio (p < 0.01). Echocardiographic-determined measurements of left ventricular systolic and diastolic function were unaltered by spironolactone. Therefore, spironolactone has potentially beneficial effects on cardiac adrenergic tone, divalent cation balance, and ventricular arrhythmias in patients with chronic heart failure who are already receiving standard doses of ACE inhibitors. All of these factors could be significant in the prevention of sudden cardiac death in this population.